COVID-19 studies

covid vaccine 457x220

Nationally prioritised and/or expedited studies open at Southampton

See NIHR'S list of all national priority studies here.


Full title: Randomised evaluation of COVID-19 therapy

Comparison of existing HIV treatment (Lopinavir-Ritonavir) and antiinflammatory steroid (dexamethasone) in treating COVID-19.

Local PI: Sophie Fletcher (
Contact: or 023 8120 8141

Trial website: 

Find out more


Full title: A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia

A multi-centre international adaptive platform trial of critically ill patients with community acquired pneumonia, including COVID-19. It has multiple domains to evaluate multiple interventions simultaneously, including antivirals and immunomodulators, and will also evaluate potential interactions.

Local PI: Ahilanadan Dushianthan (
Contact email:

Trial website:

Find out more

COVID-19 vaccine trial

Full title: A phase I/II study to determine efficacy, safety and immunogenicity of the candidate COVID-19 vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers

Healthy adults aged 18-55 can join a trial of Oxford University's candidate COVID-19 vaccine ChAdOx1 nCoV-19 at Southampton. Developed by Oxford University, this vaccine is being tested for how strongly it stimulates the body's immune defences, protects against infection and its safety.  

Local PI: Prof Saul Faust (

Find out more and register interest: 


Full title: Clinical Characterisation Protocol for Severe Emerging Infection

This study is designed for the rapid, coordinated clinical investigation of patients with confirmed novel coronavirus infection. The study has been designed to maximize the likelihood that as much data as possible is collected and shared rapidly in a format that can be easily aggregated, tabulated and analysed across many different settings globally. The study is designed to have some level of flexibility in order to ensure the broadest acceptance.

Local PI: Ahilanadan Dushianthan (


Online questionnaire monitoring coronavirus infection children and adults vulnerable to infection.

Local PI: Dr Hans de Graaf (

Find out more

SARS-CoV-2 infection

A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection.

Local PI: Prof Tom Wilkinson (

What's the STORY

Prevalence of viral antibodies in the child-age population (0 – 24 years) through analysis of routine blood samples, expanding to include COVID-19.

Local PI: Prof Saul Faust (

Study website:


Biofire rapid diagnostics in COVID-19.

Local PI: Dr Tristan Clark (


Full title: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients

There are currently no approved therapeutic agents available to treat coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS CoV 2), the causative agent of COVID 19 disease, and there is an urgent public health need for rapid development of such interventions.

This adaptive platform study is designed to rapidly assess multiple candidate agents as treatments for COVID 19. 

Six potential drugs will initially enter the programme, with the first three of these beginning Phase 2 studies, which assess how well they work and their safety. Those showing promise will be fed into UK's large-scale COVID-19 studies such as the RECOVERY trial.

Local PI: Dr Mark Jones

Find out more


Full title: Genetics of susceptibility and mortality in critical care

Susceptibility to COVID-19 is almost certainly, in part, genetic. GenOMICC can find the genes that cause susceptibility, which may help us to prioritise treatments to respond to the global crisis. GenOMICC was designed for this crisis. Since 2016, the open, global GenOMICC collaboration has been recruiting patients with emerging infections, including COVID-19. All patients with confirmed COVID-19 in critical care are eligible for GenOMICC.

Local PI: Dr Rebecca Cusack (

UKOSS: Pandemic Influenza in Pregnancy

Full title: Maternal and Perinatal Outcomes of Pandemic Influenza in Pregnancy

The study will use the UK Obstetric Surveillance System (UKOSS) to collect information about all pregnant women admitted to hospital who are confirmed to have the virus infection. Specifically, the study will describe incidence, management and outcomes of COVID-19 in pregnancy and identify factors associated with better outcomes for women and their babies.

Local PI: Dr Nazia Irsnad


Full title: Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis

The overall aim of DIAMONDS is to design new diagnostic tests that can tell quickly and accurately what illness a patient has when they come to hospital with common symptoms such as fever. It is recruiting children and adults of all ages with suspected and proven COVID-19.  

Local PI: Prof Saul Faust (

Other COVID-19 studies at Southampton

Understanding impacts of COVID-19 restrictions on young people

A study engaging young people in Southampton and surounding areas about their experiences and concerns under lock down measures, to identify and develop solutions that support their wellbeing, mental and physical health.

Local PI: Prof Mary Barker (

Examining T cell responses in virus infection (ExCel)

A study looking at blood and tissue samples from patients who are known to have a viral infection to help us better understand how the immune system works. The purpose of this project is to improve our knowledge of how the immune system works in lung diseases.

Local PI: Dr Serena Chee

Public Health England Seroepidemiology Programme 2020 + COVID-19 Response

Ongoing study measuring prevalence of viral antibodies in the population through analysis of routine blood samples, expanding to include COVID-19.


Full title: How to support children with cancer and their parents during the COVID-19 outbreak?: understanding experiences, information and support needs, and decision-making

This study aims to:

  • explore experiences, information and support needs and decision-making
  • explore how these change over time as the situation with COVID-19 evolves
  • evaluate whether online intervention iHOPE to support families helps reduce anxiety and stress

To take part in the SHARE study survey, parents should visit and children and young people should visit

Local PI: Dr Juliet Gray (

Research team contact:

Personal Respirator Southampton (PeRSo)

Personal Resiprator Southampton (PeRSo) Personal protective equipment (PPE) to be worn by frontline NHS staff exposed to risk of COVID-19 infection, without interruption for several hours, delivering clean HEPA filtered air into a face mask.

Local PI: Prof Paul Elkington

Investigating and forecasting the impact of COVID-19 in Emergency Departments

To evaluate the impact of Covid-19 on the operations of Emergency Departments. Answering questions such as: at what times of day are the ED busiest with COVID-19 cases.

Local PI: Dr Michael Kiuber (

COVID-19 Emergency Response Assessment (CERA)

The CERA study will aim to understand the evolving and cumulative effects of working during the COVID-19 outbreak on the psychological health of those physicians working in the Emergency Department during the pandemic wave of the 2020 UK outbreak.

Local PI: Dr Peter Ellis (

Germ Defence

Full title: Rapid co-design, implementation and evaluation of a digital behaviour change intervention to improve hand hygiene and limit spread of the COVID-19 outbreak

Project to evaluate how the existing digital public health intervention Germ Defence can be very rapidly adapted and optimised for the changing needs of an infection outbreak, using novel participatory-co-design methods.

PI: Prof Lucy Yardley (